News & Events

Learn about what's new with CMC Biologics

CMC Biologics and Zymeworks Enter into Agreement for Process Development and Clinical Manufacture of Bi-Specific Antibody Product Candidate

News

cmclogozymeworks
Seattle, WA and Vancouver, BC – September 3, 2014
CMC Biologics, Inc., a global leader in process development and contract manufacturing, and Zymeworks Inc., a Canadian biotherapeutics company and a world leader in the development of antibody therapeutics, have entered into a Master Services Agreement for process development, formulation development and cGMP clinical manufacturing of a recombinant human IgG1 bi-specific (heterodimeric) antibody.